About us
Our science
Background & GoalApproachTherapeutic TargetsPublications
Our programsPatientsInvestorsCareers
Our programs

We are advancing a broad pipeline of potentially best-in-class antibodies

ZUMILOKIBART
APG279
APG273
We believe zumilokibart (APG777) and our combination strategies will enable us to develop the most effective, safe options for people living with I&I conditions. Zumilokibart has pipeline-in-a-product potential, and is currently being evaluated in atopic dermatitis, with plans to advance trials in asthma and eosinophilic esophagitis.
A 3D visualization of an APG777 molecular structure. The molecule is an antibody with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG990 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG333 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.A 3D visualization of an APG777 molecular structure. The molecule is an antibody with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG990 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG333 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.

Pipeline

Potential best-in-class monotherapy in AD

Higher exposures for better efficacy with less frequent dosing
Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Next anticipated milestones
APG777 is now Zumilokibart!

ZUMILOKIBART

(APG777)
IL-13
Atopic Dermatitis (Positive Part B 16-week data)
Phase 2 complete
Atopic Dermatitis (Positive Part B 16-week data)
Next anticipated milestones:

2H 2026: Phase 3 trial initiation

Asthma (Positive Ph1b data)
Phase 1 complete
Asthma (Positive Ph1b data)
Next anticipated milestones:

1H 2027: ASPIRE Phase 2b trial initiation

Eosinophilic Esophagitis
Phase 1 complete
Eosinophilic Esophagitis
Next anticipated milestones:

2H 2026: ELEVATE Phase 2a trial initiation

Next anticipated milestones:

Potential first-or best-in-class combination approaches

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Next anticipated milestones

APG279

(APG777 + APG990)
IL-13 + OX40L
Atopic Dermatitis
Phase 1 in-progress
Atopic Dermatitis
Next anticipated milestones:

2H 2026: Phase 1b PoC data (against DUPIXENT; fully enrolled)

Next anticipated milestones:
Next anticipated milestones:
Next anticipated milestones:

APG273

(APG777 + APG333)
IL-13 + TSLP
Asthma / COPD
Preclinical in-progress
Asthma / COPD
Next anticipated milestones:

2026: Additional trial plans to be announced

Next anticipated milestones:
Next anticipated milestones:
Next anticipated milestones:
APG808
IL-4Rα
announced positive interim Phase 1b asthma results in May 2025

Our programs

ZUMILOKIBART (APG777)

Zumilokibart (APG777) is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of atopic dermatitis (AD)

In head-to-head preclinical studies, zumilokibart showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. AD is a chronic inflammatory skin disorder that affects approximately 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom, 40 percent of which have moderate-to-severe disease.

Based on results from the APEX clinical program, Apogee plans to initiate Phase 3 trials of zumilokibart for moderate-to-severe atopic dermatitis in the second half of 2026, pending regulatory interactions. Apogee has also disclosed planned trial designs for its asthma and eosinophilic esophagitis (EoE) programs, further supporting zumilokibart’s potential as a pipeline-in-a-product opportunity across multiple I&I diseases, with plans to further evaluate opportunities to develop zumilokibart for other I&I indications including chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and prurigo nodularis.

APG279

APG279 is designed to address multiple immune signaling intervention points through the dual inhibition of IL-13 and OX40L, which we believe could provide potential first-in-class combination treatment for people living with AD and other I&I indications.

Apogee plans to develop zumilokibart and APG990 together as a potential first-in-class coformulation combining deep and sustained inhibition of Type 2 inflammation via zumilokibart’s inhibition of IL-13 with broader inhibition of Type 1-3 inflammation through APG990’s inhibition of OX40L.

APG279 is currently in a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of zumilokibart + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. In preclinical studies, the combination of APG279 has been shown to drive closer to JAK-like inhibition of Type 1, 2, and 3 signaling compared to approved or in-development biologics, with the potential for best-in-class dosing and better tolerability in AD and a variety of other I&I diseases.

APG273

APG273 is designed to address both central and local drivers of obstructive airway disease and potentially break through the efficacy ceiling observed with monotherapies in asthma and COPD.

Apogee plans to evaluate zumilokibart in a Phase 2b trial in patients with asthma, and will announce additional clinical plans for APG273, in 2026 to support advancement into future combination trials in asthma and COPD.

In preclinical studies, the combination of zumilokibart and APG333 has been shown to drive broader and deeper inhibition of inflammation centrally with deeper impact on local airway responses compared to approved or in-development biologics, with the potential for a significantly less frequent dosing schedule.